Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea announced a collaboration with Omico, Australia's leading precision oncology screening organization, to connect cancer patients with biomarker-matched clinical trials. The partnership pairs Fortrea's oncology trial experience with Omico's PrOSPeCT program, Australia's largest cancer genomics initiative, which has more than 23,000 consented patients and referrals from over 1,600 clinicians. Omico will provide Fortrea's clients genomic profiling, trial-matching and patient referral pathways in Australia to improve site selection and recruitment speed.
Key figures
- Referring clinicians
- 1600
- Consented patients omico
- 23000
- Fortrea oncology physicians
- 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.